Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in unresectable pancreatic cancer
2021-005874-24Phase 4Active
- Sponsor
- Juan Enrique DomÃnguez Muñoz
- Start
- Feb 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pancreatin in exocrine pancreatic insufficiency (EPI) and pancreatic cancer (PC) (2 arms), sponsored by Juan Enrique DomÃnguez Muñoz. Primary endpoint: Change in body weight. Started Feb 2022; status: active.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2021-005874-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005874-24.